RESEARCH LETTER
 
TOPICS
REFERENCES (15)
1.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49.
 
2.
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2133-61.
 
3.
Gu ZC, Dai MF, Wei Q, et al. Enhancing thromboprophylaxis after colorectal cancer surgery in China: bridging the gap between evidence and implementation through pathway optimization. Pharmacotherapy 2024; 44: 549-57.
 
4.
Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34: 452-67.
 
5.
Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20: e566-81.
 
6.
Hanna N, Brogly SB, Wei XS, et al. Incidence and risk factors of venous thromboembolism following hepatectomy for colorectal metastases: a population-based retrospective cohort study. World J Surg 2021; 46: 180-8.
 
7.
Liang Z, Huang X, Mao J, et al. The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer. BMC Gastroenterol 2025; 25: 240.
 
8.
Qin L, Liang Z, Xie J, Li X. Estimating venous thromboembolism risk in metastatic colorectal cancer inpatients: validation of existing risk scores and development of new risk scores. Clin Appl Thromb Hemost 2023; 29: 10760296231196859.
 
9.
Donahue CA, Brinton DL, Booth AT, et al. Guideline-concordant extended pharmacologic venous thromboembolism prophylaxis utilization after colorectal cancer resection is low regardless of patient factors or hospital characteristics. Dis Colon Rectum 2024; 68: 417-25.
 
10.
Vrotniakaite-Bajerciene K, Carrier M, Wang TF. Risk factors and management of cancer-associated thrombosis: the ongoing battle between efficacy and safety of anticoagulation. Med Clin North Am 2025; 109: 857-73.
 
11.
Nakamura M, Sakon M, Sasako M, et al. Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis. Int J Clin Oncol 2024; 29: 407-16.
 
12.
Su Y, Chen J, Du L, Liu X. Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in colorectal cancer: a meta-analysis. Ann Med 2025; 57: 2530689.
 
13.
Muliawan GK, Leung CON, Lee TKW. Beyond the role of transcobalamin 1 (TCN1) as a vitamin B12-binding protein in hepatocellular carcinoma. Cancer Res 2024; 84: 2785.
 
14.
Erdogdu IH, Orenay-Boyacioglu S, Boyacioglu O, et al. Microsatellite instability and somatic gene variant profile in solid organ tumors. Arch Med Sci 2024; 20: 1672-9.
 
15.
Chen Y, Liang J, Chen S, et al. Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer. Mol Cancer 2024; 23: 196.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top